Prognostic relevance of pericardial effusion in patients with malignant diseases

TO THE EDITOR: Malignancy is a common cause of pericardial effusion, and malignant pericardial effusion is a serious manifestation in advanced malignancies [1]. Malignancy-related pericardial effusion is associated with significantly decreased patient survival [1]. Slight malignant pericardial effusions are frequently asymptomatic; however, symptomatic patients often present with cardiac tamponade, which can rapidly lead to cardiovascular collapse or death [2]. Therefore, early diagnosis and timely treatment may decrease a patient’s short-term risk of death. We evaluated both the etiology and prognosis of pericardial involvement in several malignancies.

We retrospectively reviewed the records of 215 patients (126 males and 89 females) with pericardial effusion and malignant diseases, including solid tumors and hematological malignancies, from January 1991 to December 2010. In all cases, the clinical diagnosis was confirmed by pathological examination of the primary tumor site. All patients underwent pericardiocentesis, and pericardial fluid analyses were performed for cytology. We analyzed the incidence of the etiology of malignancies and overall survival according to the results of the pericardial fluid analysis. Overall survival was calculated from the day of initial diagnosis to the date of patient’s death from any other cause or to the latest follow-up date.

Among 215 patients, 113 (52.6%) showed pericardial involvement in their malignant diseases. The etiological diagnosis and pericardial fluid analysis results are summarized in Table 1. Pericardial involvement of malignancy was most frequent in breast carcinoma (85.0%), followed by lung adenocarcinoma (61.9%), gastric adenocarcinoma (58.8%), thymic carcinoma (33.3%), and esophageal squamous cell carcinoma.

| Malignancies                              | Patients, N (%) | Patients with pericardial involvement, N (%) |
|------------------------------------------|-----------------|---------------------------------------------|
| Solid tumors                             |                 |                                             |
| Lung adenocarcinoma                      | 105 (48.8)      | 65 (61.9)                                   |
| Ductal cell carcinoma, breast            | 20 (9.3)        | 17 (85.0)                                   |
| Gastric adenocarcinoma                   | 17 (7.9)        | 10 (58.8)                                   |
| Esophageal squamous cell carcinoma       | 17 (7.9)        | 3 (17.6)                                    |
| Hepatocellular carcinoma                 | 11 (5.1)        | 1 (9.1)                                     |
| Cholangiocarcinoma                       | 3 (1.4)         | 0 (0.0)                                     |
| Thymic carcinoma                         | 9 (4.2)         | 3 (33.3)                                    |
| Other solid tumorsa)                     | 23 (10.7)       | 9 (39.1)                                    |
| Hematological malignancies               |                 |                                             |
| Lymphoma                                 | 6 (2.8)         | 5 (83.3)                                    |
| Other hematologic malignanciesb)         | 4 (1.9)         | 0 (0.0)                                     |
| Total                                    | 215 (100.0)     | 113 (52.6)                                  |

aAngiosarcoma (N=2), cervix cancer (N=1), colorectal cancer (N=4), embryonal carcinoma (N=1), endodermal sinus tumor (N=2), endometrial cancer (N=1), glottic cancer (N=1), metastatic cancer of unknown origin (N=1), neuroblastoma (N=3), osteosarcoma (N=1), rhabdomyosarcoma (N=1), salivary duct carcinoma (N=1), sarcomatoid carcinoma (N=1), synovial sarcoma (N=1), thyroid cancer (N=2).
bAcute myeloid leukemia (N=2), chronic myelogenous leukemia (N=1), myelodysplastic syndrome (N=1).
Fig. 1. Overall survival according to pericardial involvement in the malignant disease. The pericardial involvement group had a significantly poorer survival rate than the non-pericardial involvement group (P<0.002, pericardial involvement group vs. non-pericardial involvement group).

carcinoma (17.6%). In a survival analysis using the Cox proportional hazards model, the pericardial involvement group showed significantly poorer survival rates than the non-pericardial involvement group (hazard ratio, 2.157; 95% confidence interval, 1.327-3.507; P=0.002). The median survival time was significantly longer in patients with no evidence of pericardial involvement in their malignant diseases than in those with pericardial involvement in malignancy (118.2 months vs. 34.8 months; P=0.001) (Fig. 1).

In studies, the most common cause of malignant pericardial effusion was lung cancer (34-76%), followed by breast cancer (10-17%) [1, 3, 4]. However, in the present study, ductal cell carcinoma of the breast had the highest incidence of pericardial involvement. Because our study population included only patients with advanced-stage breast cancer, the incidence of their pericardial involvement is not representative of all patients with breast cancer.

Several treatment modalities, including both medical and surgical modalities, have been proposed for malignant pericardial effusion [5]. Timely management of pericardial effusion is important to improving the clinical outcome.

In conclusion, patients with pericardial involvement in their malignant diseases had a relatively poorer prognosis than those without pericardial involvement in malignant diseases. Cautious morphologic analyses of pericardial fluid are recommended before application of palliative or therapeutic pericardiocentesis, especially in patients with lung or breast carcinoma.

Tae-Dong Jeong, M.D., Seongsoo Jang, M.D., Ph.D., Chan-Jeoung Park, M.D., Ph.D., Hyun-Sook Chi, M.D., Ph.D.  
Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea  
Tel: +82-2-3010-4502, E-mail: hschi@amc.seoul.kr

1. Gornik HL, Gerhard-Herman M, Beckman JA. Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion. J Clin Oncol 2005;23:5211-6.  
2. Halfdanarson TR, Hogan WJ, Moynihan TJ. Oncologic emergencies: diagnosis and treatment. Mayo Clin Proc 2006;81:835-48.  
3. Dequanter D, Lothaire P, Berghmans T, Sculier JP. Severe pericardial effusion in patients with concurrent malignancy: a retrospective analysis of prognostic factors influencing survival. Ann Surg Oncol 2008;15:3268-71.  
4. Kim SH, Kwak MH, Park S, et al. Clinical characteristics of malignant pericardial effusion associated with recurrence and survival. Cancer Res Treat 2010;42:210-6.  
5. Maisch B, Ristic A, Pankuweit S. Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis 2010;53:157-63.